Abstract Background Human papillomavirus (HPV)–6/11/16/18 vaccine reduces the risk of
HPV-6/11/16/18–related cervical intraepithelial neoplasia (CIN) 1–3 or adenocarcinoma in …

This review focuses on recent publications of clinical trials of two prophylactic human
papillomavirus (HPV) vaccines: Gardasil®(Merck & Co., Inc., Whitehouse Station, NJ USA) …

The prevalence of HPV infection in Latin America is among the highest in the world. A
quadrivalent (types 6/11/16/18) human papillomavirus L1 virus‐like‐particle vaccine has …

Vaccination against human papillomavirus (HPV) promises to dramatically decrease the
incidence of HPV-related diseases, including cervical cancer. Although this vaccine is …

Identification of HPV infection as the etiologic agent of virtually all cases of cervical cancer,
as well as a proportion of other epithelial cancers, has led to development of three FDA …

Abstract Background The United States (US) Food & Drug Administration (FDA) recently
approved a human papillomavirus (HPV) vaccine with the purpose of reducing the risk of …

Recent clinical trials in young women have shown that subunit vaccines based on human
papillomavirus (HPV) 16 and HPV18 L1 virus-like particles are∼ 100% effective in short …

Human papillomavirus (HPV) has been implicated as the primary etiologic agent of cervical
cancer. Potential vaccines against high-risk HPV types are in clinical trials. We evaluated …

Objective Nine-valent human papillomavirus (9vHPV) vaccine efficacy against disease and
cervical surgeries related to all nine vaccine components was assessed compared with a …

Objectives This study aimed to systematically review the literature on the efficacy and
immunogenicity of single-dose HPV vaccination compared to no vaccination or multi-dose …